<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04253405</url>
  </required_header>
  <id_info>
    <org_study_id>IP-HCOR/RENOVATEfibrose</org_study_id>
    <nct_id>NCT04253405</nct_id>
  </id_info>
  <brief_title>RENOVATE Fibrosis: Pilot Study Comparing HFNC Versus NIPPV in Acute Respiratory Failure in Patients With Pulmonary Fibrosis</brief_title>
  <official_title>Multicentric Randomized Controlled Pilot Study Comparing High Flow Nasal Cannula Versus NonInvasive Positive Pressure Ventilation in Acute Respiratory Failure in Patients With Pulmonary Fibrosis (RENOVATE Fibrosis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital do Coracao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fisher_&amp;_Paykel Healthcare Corporation Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital do Coracao</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot multicentric randomized controlled study investigating the feasibility of recruiting
      50 pulmonary fibrosis patients in acute respiratory failure within 18 months. Additionally,
      exploratory efficacy and safety outcomes will be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RENOVATE Fibrosis is a randomized controlled trial (RCT) testing the feasibility of
      recruiting pulmonary fibrosis patients in acute respiratory failure (ARF) while also
      investigating, in a preliminary way, important efficacy and safety outcome´s effect size.

      RENOVATE Fibrosis will recruit centrally adjudicated pulmonary fibrosis cases in acute
      respiratory distress to be randomized to HFNC or NIPPV. Efficacy and safety outcomes measured
      are dyspnea variation, physiological variables, comfort, ETI rate, mortality in 28 and 90
      days.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 randomized controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment feasibility</measure>
    <time_frame>18 months</time_frame>
    <description>Recruitment of 50 pulmonary fibrosis patients in acute respiratory failure in 18 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dyspneia variation (Borg scale)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory frequency variation</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxygen saturation/fraction of inspired oxygen (SpO2/FiO2) variation</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carbon dioxide arterial partial pressure (PaCO2) variation</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Comfort visual analog scale variation</measure>
    <time_frame>7 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Endotracheal intubation (ETI) rate</measure>
    <time_frame>7 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Respiratory Failure</condition>
  <condition>Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>High Flow Nasal Cannula (HFNC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The HFNC (Airvo2 Fisher &amp; Paykel, Auckland, New Zealand) consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers flow up to 60 L/ min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-invasive positive pressure ventilation (NIPPV)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NIPPV will be performed using the devices available on centers. Both a dedicated NIPPV device or an invasive mechanical ventilator with NIPPV mode are accepted. The interface should be an oronasal or full face mask.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High Flow Nasal Catheter</intervention_name>
    <description>HFNC will be delivered through AIRVO2. FiO2 from 21 to 100% and heated humidified gas flow up to 60 l / min with temperature of the circuit maintained at 37 degrees.
Oxygen flow will be offered through a humidified nasal catheter. Flow and FiO2 will be titrated according to the protocol to maximize the patient´s comfort and SpO2</description>
    <arm_group_label>High Flow Nasal Cannula (HFNC)</arm_group_label>
    <other_name>Optiflow</other_name>
    <other_name>Airvo</other_name>
    <other_name>trans-nasal insufflation</other_name>
    <other_name>Nasal High Flow</other_name>
    <other_name>High Flow Nasal Cannula</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Noninvasive positive pressure ventilation (NIPPV)</intervention_name>
    <description>NIPPV will be performed using a facial mask (either oronasal or full face). NIPPV will deliver pressures and FiO2 according to the protocol.</description>
    <arm_group_label>Non-invasive positive pressure ventilation (NIPPV)</arm_group_label>
    <other_name>BiPAP</other_name>
    <other_name>Non-invasive ventilation</other_name>
    <other_name>Non-invasive positive pressure ventilation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Sequential adult patients 18 years of age or older admitted to the ICU
        or emergency department with pulmonary fibrosis and acute onset of respiratory failure that
        meets criteria A and B bellow.

        A. Pulmonary fibrosis will be defined by all of the criteria below:

          -  presence of Velcro-type crackles on physical examination

          -  diffuse pulmonary fibrosis on imaging confirmed by real-time central adjudication

        B. Acute respiratory failure (ARF) will be defined by hypoxemia evidenced by SpO2 &lt;90% or
        PaO2 &lt;60 mmHg in room air and at least two of the criteria below within the last four
        weeks:

          -  worsening dyspnea

          -  worsening breathing effort

          -  worsening gas exchange (worsening SpO2 or paO2)

          -  worsening respiratory rate, above 25 irpm

        Exclusion Criteria:

          -  Pulmonary fibrosis secondary to progressive massive fibrosis (silicosis), or any other
             tumor form of fibrosis;

          -  Significant pulmonary arterial hypertension characterized by: Right ventricular
             failure on Doppler echocardiogram or Cardiac index &lt;2L / min / m2 in catheterization
             of right chambers;

          -  Pneumothorax or extensive pleural effusion as the main determinant of IRPA in the
             assessment of the attending physician;

          -  Cardiogenic pulmonary congestion as the main determinant of IRPA in the assessment of
             the attending physician;

          -  Presence of delirium or non-cooperation at the time of randomization;

          -  Anatomical facial abnormalities;

          -  Incoercible vomiting or hypersecretion of the airways;

          -  Use of continuous VNIPP or HFNC for more than 8h before randomization;

          -  pregnancy;

          -  Refusal to participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leticia Kawano-Dourado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital do Coração</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Israel Maia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital do Coração</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leticia Kawano Dourado, MD</last_name>
    <phone>+55 11 3053-6611</phone>
    <phone_ext>8209</phone_ext>
    <email>ldourado@hcor.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karina Negrelli, Asst</last_name>
    <phone>+55 11 3053-6611</phone>
    <phone_ext>8201</phone_ext>
    <email>knegrelli@hcor.com.br</email>
  </overall_contact_backup>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 31, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>March 22, 2020</last_update_submitted>
  <last_update_submitted_qc>March 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data sharing plan - under construction</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

